Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung
Executive Summary
The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.
You may also be interested in...
AstraZeneca Makes European IO Debut With Imfinzi Lung Cancer Approval
Imfinzi will be the fourth PD-1/L1 inhibitor approved for lung cancer in Europe, but AstraZeneca could carve out a niche by being indicated for sequential use following chemoradiation.
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.